ATE256127T1 - Betacarbolinderivate als phosphodiesterase- inhibitoren - Google Patents

Betacarbolinderivate als phosphodiesterase- inhibitoren

Info

Publication number
ATE256127T1
ATE256127T1 AT01935038T AT01935038T ATE256127T1 AT E256127 T1 ATE256127 T1 AT E256127T1 AT 01935038 T AT01935038 T AT 01935038T AT 01935038 T AT01935038 T AT 01935038T AT E256127 T1 ATE256127 T1 AT E256127T1
Authority
AT
Austria
Prior art keywords
betacarboline
derivatives
phosphodiesterase inhibitors
phosphodiesterase
inhibitors
Prior art date
Application number
AT01935038T
Other languages
English (en)
Inventor
Zhihua Sui
Mark J Macielag
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE256127T1 publication Critical patent/ATE256127T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT01935038T 2000-05-17 2001-05-03 Betacarbolinderivate als phosphodiesterase- inhibitoren ATE256127T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20466700P 2000-05-17 2000-05-17
PCT/US2001/014357 WO2001087038A2 (en) 2000-05-17 2001-05-03 β-CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE

Publications (1)

Publication Number Publication Date
ATE256127T1 true ATE256127T1 (de) 2003-12-15

Family

ID=22758909

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01935038T ATE256127T1 (de) 2000-05-17 2001-05-03 Betacarbolinderivate als phosphodiesterase- inhibitoren

Country Status (31)

Country Link
US (2) US6492358B2 (de)
EP (1) EP1289985B1 (de)
JP (1) JP5014551B2 (de)
KR (1) KR20030031482A (de)
CN (1) CN1255403C (de)
AR (1) AR028576A1 (de)
AT (1) ATE256127T1 (de)
AU (2) AU2001261167B2 (de)
BG (1) BG66141B1 (de)
CA (1) CA2409715C (de)
CZ (1) CZ20023934A3 (de)
DE (1) DE60101479T2 (de)
DK (1) DK1289985T3 (de)
ES (1) ES2211806T3 (de)
GE (1) GEP20053511B (de)
HR (1) HRP20020910B1 (de)
HU (1) HUP0302412A3 (de)
IL (2) IL152873A0 (de)
MX (1) MXPA02011426A (de)
MY (1) MY128479A (de)
NO (1) NO324251B1 (de)
NZ (1) NZ522731A (de)
PL (1) PL205507B1 (de)
PT (1) PT1289985E (de)
RU (1) RU2271358C2 (de)
SK (1) SK16972002A3 (de)
TR (1) TR200302309T4 (de)
TW (1) TWI286553B (de)
UA (1) UA74826C2 (de)
WO (1) WO2001087038A2 (de)
ZA (1) ZA200210111B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062339A1 (en) * 2000-12-08 2002-08-15 Smithkline Beecham Corporation Antibacterial compounds
US6900220B2 (en) * 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
JP4220779B2 (ja) * 2001-02-12 2009-02-04 リリー アイコス リミテッド ライアビリティ カンパニー 化学化合物
MXPA03007142A (es) * 2001-02-12 2004-05-24 Lilly Icos Llc Derivados de carbolina.
CA2441792C (en) * 2001-04-25 2010-08-03 Lilly Icos Llc Carboline derivatives as inhibitors of phosphodiesterase 5 (pdes) for the treatment of cardiovascular diseases and erectile dysfunction
WO2002098875A1 (en) * 2001-06-05 2002-12-12 Lilly Icos Llc Carboline derivatives as pde-5 inhibitors
US6984641B2 (en) 2001-06-21 2006-01-10 Lilly Icos Llc. Carboline derivatives as PDE5 inhibitors
PT1448562E (pt) 2001-11-14 2007-08-31 Ortho Mcneil Pharm Inc Derivados da pirroloquinolona tetracíclica substituídos, úteis como inibidores da fosfodiesterase
AU2003216174C1 (en) * 2002-02-07 2010-01-28 University Of Tennessee Research Foundation Treating benign prostate hyperplasia with SARMs
EP1534707B9 (de) * 2002-06-19 2008-11-26 Janssen Pharmaceutica N.V. SUBSTITUIERTE 2,4-DIHYDROPYRROLOç3,4B]CHINOLIN-9-ONDERIVATE, DIE SICH ALS PHOSPHODIESTERASEINHIBITOREN EIGNEN
EP1637521B1 (de) * 2003-06-23 2013-06-19 Ono Pharmaceutical Co., Ltd. Neue tricyclische heterocyclusverbindung
JP2007518822A (ja) 2004-01-23 2007-07-12 カイロン コーポレイション 抗癌剤としてのテトラヒドロカルボリン化合物
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
ZA200608176B (en) 2004-03-15 2008-05-28 Ptc Therapeutics Inc Carboline derivatives useful in the inhibition of angiogenesis
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
PT1829874E (pt) * 2004-12-22 2014-04-10 Ono Pharmaceutical Co Composto tricíclico e sua utilização
GB2422828A (en) * 2005-02-03 2006-08-09 Hunter Fleming Ltd Tricyclic cytoprotective compounds comprising an indole residue
WO2007016361A2 (en) * 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP2314289A1 (de) 2005-10-31 2011-04-27 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2008030651A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2009011836A1 (en) * 2007-07-19 2009-01-22 Merck & Co., Inc. Beta carboline derivatives as antidiabetic compounds
JP2011505373A (ja) 2007-11-30 2011-02-24 ビオタ サイエンティフィック マネージメント ピーティーワイ リミテッド 抗菌剤としての２環式ｐｐａｔ阻害剤
US8716308B2 (en) 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
WO2009120717A2 (en) 2008-03-24 2009-10-01 Medivation Technologies, Inc. Pyrido [3, 4-b] indoles and methods of use
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2010107485A1 (en) * 2009-03-17 2010-09-23 The Trustees Of Columbia University In The City Of New York E3 ligase inhibitors
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003005A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011038162A1 (en) * 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido(3,4-b)indoles and methods of use
JP5821848B2 (ja) * 2010-07-06 2015-11-24 小野薬品工業株式会社 テトラヒドロカルボリン誘導体
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
TW201309698A (zh) 2011-03-18 2013-03-01 Ono Pharmaceutical Co 四氫咔啉衍生物
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN107216327A (zh) * 2017-06-27 2017-09-29 山东大学 5型磷酸二酯酶抑制剂及其制备方法和用途
WO2021046194A1 (en) * 2019-09-03 2021-03-11 The Regents Of The University Of Colorado A Body Corporate Tryptoline-based benzothiazoles and their use as antibiotics and antibiotic resistance-modifying agents
US12419888B2 (en) * 2020-12-11 2025-09-23 Institut De Cardiologie De Montreal Methods of treating elevated plasma cholesterol
JP2024502270A (ja) 2020-12-23 2024-01-18 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー エストロゲン受容体調節薬
CN119462646A (zh) * 2024-11-07 2025-02-18 江苏科技大学 一种取代的四氢-β-咔啉衍生物、其合成方法及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1055203A (en) 1964-09-16 1967-01-18 Ici Ltd -ß-carboline derivatives, a process for their manufacture, and compositions containing them
US4228168A (en) 1978-11-22 1980-10-14 Tanabe Seiyaku Co., Ltd. Azepino [1,2,3-lm]-β-carboline compounds and pharmaceutical composition thereof
NZ194747A (en) 1979-08-29 1988-11-29 Schering Ag 9h-pyrido(3,4-b)indol-3-ylcarboxylic acid derivatives
WO1988002751A1 (fr) 1986-10-13 1988-04-21 Asahi Kasei Kogyo Kabushiki Kaisha Derives de pyridine
CS262100B1 (cs) * 1987-07-17 1989-02-10 Protiva Miroslav 1-substituované 2- [ (4-methyl-l-piperazinyl)acetyl ] -2,3,4,9- -tetrahydro-lH-pyrido( 3,4-b)indoly a jejich hydrochloridy
EP0300541B1 (de) 1987-07-20 1996-03-27 Duphar International Research B.V 8,9-Anellierte 1,2,3,4-Tetrahydro-beta-carbolin-Derivate
FR2619112B1 (fr) * 1987-08-07 1989-11-17 Synthelabo Derives de (piperidinyl-4)methyl-2 benzo(b)furo(2,3-c) pyridines, leur preparation et leur application en therapeutique
US4971974A (en) 1988-06-16 1990-11-20 Neurex Corporation Benzothiophenes as appetite suppressants
WO1990001483A1 (fr) 1988-08-11 1990-02-22 Asahi Kasei Kogyo Kabushiki Kaisha Derives de tetrahydropyridine
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
FR2663935A1 (fr) 1990-06-27 1992-01-03 Adir Nouveaux 1,2,3,4,5,6-hexahydroazepino [4,5-b] indoles et 1,2,3,4-tetrahydrobethacarbolines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
ES2204932T3 (es) * 1994-09-12 2004-05-01 Eli Lilly And Company Limited Moduladores serotonergicos.
FR2724384B1 (fr) 1994-09-14 1999-04-16 Cemaf Nouveaux derives de la 3,4-dihydro beta-carboline agonistes de la melatonine, leur procede de preparation et leur utilisation a titre de medicament
DE4436190A1 (de) 1994-10-10 1996-04-11 Gerhard Prof Dr Bringmann Halogenierte ß-Carbolin-Derivate, Verfahren zu ihrer Herstellung und Verwendung dieser Substanzen zur Hemmung der Atmungskette
DE4436509A1 (de) 1994-10-13 1996-04-18 Hoechst Schering Agrevo Gmbh Substituierte Spiroalkylamino- und alkoxy-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5968910A (en) * 1994-11-30 1999-10-19 Jan M. R. Balzarini Compositions containing two or three inhibitors of different HIV reverse transcriptases
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
FR2748026B1 (fr) 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EE9800390A (et) * 1996-05-10 1999-06-15 Icos Corporation Karboliini derivaadid
TW422837B (en) 1996-05-31 2001-02-21 Mochida Pharm Co Ltd Pyridocarbazole deivatives having cGMP-PDE inhibitory activity
AU6290998A (en) 1997-03-07 1998-09-29 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and use
US6043252A (en) 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
WO2000002878A1 (en) 1998-07-11 2000-01-20 University Of Bristol Compounds having activity at imidazoline receptors
FR2796644B1 (fr) * 1999-07-23 2001-09-07 Adir Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
TWI286553B (en) 2007-09-11
AU6116701A (en) 2001-11-26
WO2001087038A3 (en) 2002-05-16
DE60101479T2 (de) 2005-04-28
CA2409715C (en) 2010-09-14
TR200302309T4 (tr) 2004-02-23
US6492358B2 (en) 2002-12-10
CZ20023934A3 (cs) 2003-10-15
US20030166641A1 (en) 2003-09-04
UA74826C2 (en) 2006-02-15
AU2001261167B2 (en) 2006-10-05
EP1289985A2 (de) 2003-03-12
AR028576A1 (es) 2003-05-14
EP1289985B1 (de) 2003-12-10
BG107285A (bg) 2003-07-31
NZ522731A (en) 2004-09-24
DK1289985T3 (da) 2004-04-05
HRP20020910A2 (en) 2004-12-31
ES2211806T3 (es) 2004-07-16
CN1255403C (zh) 2006-05-10
MXPA02011426A (es) 2004-09-06
RU2271358C2 (ru) 2006-03-10
GEP20053511B (en) 2005-05-10
MY128479A (en) 2007-02-28
SK16972002A3 (sk) 2003-11-04
HUP0302412A3 (en) 2007-02-28
PL365445A1 (en) 2005-01-10
US6864253B2 (en) 2005-03-08
PT1289985E (pt) 2004-03-31
JP2003533453A (ja) 2003-11-11
JP5014551B2 (ja) 2012-08-29
HUP0302412A2 (hu) 2003-11-28
NO324251B1 (no) 2007-09-17
WO2001087038A2 (en) 2001-11-22
DE60101479D1 (en) 2004-01-22
PL205507B1 (pl) 2010-04-30
HRP20020910B1 (hr) 2011-02-28
NO20025527D0 (no) 2002-11-18
IL152873A (en) 2012-01-31
CA2409715A1 (en) 2001-11-22
NO20025527L (no) 2003-01-16
ZA200210111B (en) 2004-03-12
BG66141B1 (bg) 2011-07-29
US20020010189A1 (en) 2002-01-24
KR20030031482A (ko) 2003-04-21
HK1051368A1 (en) 2003-08-01
CN1446217A (zh) 2003-10-01
IL152873A0 (en) 2003-06-24

Similar Documents

Publication Publication Date Title
ATE256127T1 (de) Betacarbolinderivate als phosphodiesterase- inhibitoren
ATE278690T1 (de) Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
ATE437862T1 (de) Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
DK1319003T3 (da) Xanthin-phosphodiesterase V-inhibitorer
ATE445613T1 (de) Indolylmaleimidderivative als proteinkinase-c- inhibitoren
ATE372988T1 (de) Pyrimidin-derivate
ATE339403T1 (de) Pyrrolderivate als phosphodiesterase vii-hemmer
DE50107316D1 (de) Neue substituierte imidazotriazinone als pde ii-inhibitoren
ATE236157T1 (de) Imidazopyridinderivate als phosphodiesterase vii- hemmer
DE60203529D1 (de) Indolderivate als cox-ii-inhibitoren
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
ATE334114T1 (de) Substituierte c-cyclohexylmethylamin-derivate
ATE428420T1 (de) Substituierte 8-arylchinoline als phosphodiesterase-4-hemmer
ATE300945T1 (de) Isoxazolderivate als phosphodiesterase vii-hemmer
EP1570847A4 (de) Phosphodiesterase 10a-hemmer
ATE282021T1 (de) Substituierte aminomethyl-phenyl- cyclohexanderivate
DE50103035D1 (de) Substituierte 1-aminobutan-3-ol-derivate
ATE247121T1 (de) Imidazolderivate als phosphodiesterase vii-hemmer
DE60118941D1 (de) Pyrrolidin-2-carbonsäure-hydrazid-derivate als metalloprotease-inhibitoren
ATE361274T1 (de) Substituierte 5-amino-1-penten-3-ol-derivate
DK1296981T3 (da) Substituerede pyrrolopyridinonderivater som phosphodiesteraseinhibitorer
DK1246793T3 (da) Substituerede aminomethyl-phenyl-cyclohexanderivater

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1289985

Country of ref document: EP